RaySearch Laboratories AB Reports Strong First Quarter Performance

STOCKHOLM, May 9, 2025 — RaySearch Laboratories AB, a leading medical technology company specializing in cancer treatment solutions, has reported a robust performance for the first quarter of 2025. The company, which operates on the Swedish Stock Exchange, has seen significant growth in its financial metrics, reflecting its strong market position and strategic initiatives.

Financial Highlights

  • Order Intake: The company reported an order intake of SEK 409.6 million, a substantial increase from SEK 238.5 million in the same period last year.
  • Net Sales: Net sales for the quarter amounted to SEK 331.7 million, up from SEK 257.2 million.
  • Operating Profit: Operating profit reached SEK 74.8 million, compared to SEK 45.8 million in the previous year.
  • Profit After Tax: Profit after tax was SEK 56.8 million, up from SEK 36.7 million.
  • Earnings Per Share: Earnings per share before dilution were SEK 1.66, compared to SEK 1.07 last year.
  • Cash Flow: Cash flow from operating activities was SEK 146.8 million, although slightly down from SEK 167.3 million.
  • Order Backlog: The order backlog stood at SEK 1,734.4 million at the end of the period, down from SEK 1,848.0 million.

Significant Developments

The first quarter saw a notable increase in the number of radiation therapy clinics worldwide adopting RaySearch’s solutions, contributing to the strong order intake. The company’s flagship product, RayStation, continues to be a key driver of growth, offering comprehensive treatment planning systems for radiation therapy centers globally.

Market Reaction

The positive financial results have been well-received by the market, with RaySearch’s stock experiencing a two-digit rise on the Stockholm Stock Exchange. This performance underscores the company’s strong position in the health care technology sector and its ability to deliver value to shareholders.

Strategic Focus

RaySearch Laboratories AB remains committed to advancing adaptive radiation therapy through strategic alliances and continuous innovation. The company’s focus on developing cutting-edge solutions like RayStation, RayPlan, and RayCare positions it well to meet the evolving needs of the global healthcare market.

Conclusion

RaySearch Laboratories AB’s first-quarter results for 2025 highlight its robust financial health and strategic growth trajectory. With a strong order backlog and increasing adoption of its solutions, the company is well-positioned to continue its success in the competitive health care technology landscape.